Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53

International Journal of Cancer

Volumn 66, Issue 3, 1996, Pages 322-325

  Tomita, Yoshihiko ^a   Bilim, Vladimir ^a   Kawasaki, Takashi ^a   Takahashi, Kota ^a   Okan, Ismail ^b   Magnusson, Kristinn P ^b   Wiman, Klas G ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; KIDNEY NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; REFERENCE VALUES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029931307     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0     Document Type: Article

References (39)

1. AGUILAR-SANTELISES, M., MAGNUSSON, K.P., WIMAN, K.G., MELLSTEDT, H. and JONDAL, M., Progressive B-cell chronic lymphocytic leukemia frequently exhibits aberrant p53 expression. Int. J. Cancer, 58, 474-479 (1994).
2. ALDERSON, L.M, CASTLEBERG, R.L., HARSH IV, G.R., LOUIS, D.N. and HENSON, J.W., Human gliomas with wild-type p53 express bcl-2. Cancer Res., 55, 999-1001 (1995).
3. CASTLE, V.P., HEIDELBERGER, K.P., BROMBERG, J., OU, X., DOLE, M. and NUNEZ, G., Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Amer J. Pathol., 143, 1543-1550 (1993).
4. CHANDLER, D., EL-NAGGAR, A.K., BRISBAY, S., REDLINE, R.W. and MCDONNELL, T.J., Apoptosis and expression of the bcl-2 protooncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum. Pathol., 25, 789-796 (1994).
5. CHIOU, S.K., RAO, L. and WHITE, E., Bcl-2 blocks p53-dependent apoptosis Mol. cell. Biol., 14, 2556-2663 (1994).
6. CHITTENDEN, T., HARRINGTON, E.A., O'CONNOR, R., FLEMINGTON, C., LUTZ, R.J., EVAN, G.I. and GUILD, B.C., Induction of apoptosis by the Bcl-2 homologue Bak. Nature (Lond.). 374, 733-736 (1995).
7. CLEARY, M.L., SMITH, S.D. and SKLAR, J., Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 47, 19-28 (1986).
8. FANIDI, A., HARRINGTON, E.A. and EVAN, G.I., Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (Lond.), 359, 554-556 (1992).
9. FARROW, S.N., WHITE, J.H., MARTINOU, I., RAVEN, T , PUN, K.T., GRINHAM, C.J., MARTINOU, J.C. and BROWN, R., Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature (Lond.), 374, 731-733 (1995).
10. FINKE, J., FRITZEN, R., TERNES, P., TRIVEDI, P., BROSS, K.J., LANGE, W., MERTELSMANN, R. and DOLKEN, G., Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood, 80, 459-469 (1992).
11. FORMAM, J.D., The role of radiation therapy in the management of carcinoma of the kidney. Semin. Urol, 7, 195-198 (1989)
12. HAWKINS, C.J. and VAUX, D.L., Analysis of the role of bcl-2 in apoptosis. Immunol. Rev, 142, 127-139 (1994).
13. HOCKENBERY, D., NUNEZ, G., MILLIMAN, C., SCHREIBER, R.D. and KORSMEYER, S.J., Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond). 348, 334-336 (1990).
14. IKEGAKI, N., KATSUMATA, M., MINNA, J. and TSUJIMOTO, Y., Expression of bcl-2 in small-cell lung carcinoma cells. Cancer Res., 54, 6-8 (1994).
15. JAPANESE UROLOGICAL ASSOCIATION, JAPANESE SOCIETY OF PATHOLOGY AND JAPAN RADIOLOGICAL SOCIETY, General rules for clinical and pathological studies on renal-cell cancer. 2nd ed., Kanehara, Tokyo (1992).
16. KATAGIRI, A., TOMITA, Y., NISHIYAMA, T., KIMURA, M. and SATO, S., Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer. Brit. J. Cancer, 68, 125-129 (1993).
17. KAWASAKI, T., TOMITA, Y., WATANABE, R., TANIKAWA, T., KUMANISHI, T. and SATO, S., mRNA and protein expression of p53 mutations in human bladder cancer cell lines. Cancer Lett., 82, 113-121 (1994).
18. KIEFER, M.C., BRAUER, M.J., POWERS, V.C., WU, J.J., UMANSKY, S.R., TOMEI, L.D. and BARR, P.J., Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature (Lond ), 374, 736-739 (1995).
19. KORSMEYER, S.J., Bcl-2: a repressor of lymphocyte death, Immunol Today. 13, 285-288 (1992).
20. MARIN, M.C., HSU, B., MEYN, R.E., DONEHOWER, L.A., EL-NAGGAR, A.K. and MCDONNELL, T.J., Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene, 9, 3107-3112 (1994).
21. NATHAN, B., GUSTERSON, B., JADAYEL, D., O'HARE, M., ANBAZHAGAN, R., JAYATILAKE, H., EBBS, S., MICKLEM, K., PRICE, K. and GELBER, R., Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. Ann. Oncol., 5, 409-414 (1994).
22. OLTVAI, Z.N. and KORSMEYER, S.J., Checkpoints of dueling dimers foil death wishes. Cell, 79, 189-192 (1994).
23. OLTVAI, Z.N., MILLIMAN, C.L. and KORSMEYER, S.J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619 (1993).
24. RAMOVIST, T., MAGNUSSON, K.P., WANG, Y., SZEKELY, L., KLEIN, G. and WIMAN, K.G., Wild-type p53 induces apoptosis in a Burkitt lymphoma cell line that carries mutant p53. Oncogene, 8, 1495-1500 (1993).
25. SELIVANOVA, G. and WIMAN, K.G., p53: a cell cycle regulator responsive to DNA damage. Advanc. Cancer Res., 66, 143-180 (1995).
26. SHAW, P., BOVEY, R., TARDY, S., SCHLI, R., JORDAT, B. and COSTA, J., Induction of apoptosis by wild-type p53 in a human colon-tumor-derived cell line. Proc. nat. Acad. Sci. (Wash.), 89, 4495-4499 (1992).
27. SILVESTRINI, R., VENERONI, S., DAIDONE, M.G., BENINI, E., BORACCHI, P., MEZZETTI, M., DI FRONZO, G., RILKE, F. and VERONESI, U., The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph-node-negative breast cancer patients. J. nat. Cancer Inst., 86, 499-504 (1994).
28. SUZUKI, Y., TAMURA, G., SATODATE, R. and FUJIOKA, T., Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jap. J. Cancer Res., 83, 233-235 (1992).
29. SYMONDS, H., KRALL, L., REMINGTON, L., SAENZ-ROBLES, M., LOWE, S., JACKS, T. and VAN DYKE, T., p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78, 703-711 (1994).
30. TOMITA, Y., SAITO, T., SAITO, K., DITE, T., SHIMIZU, F. and SATO, S., Possible significance of VLA-4(α4β1) for hematogenous metastasis of renal-cell cancer. Int. J. Cancer, 60, 753-758 (1995).
31. TOMITA, Y., WATANABE, H., KOBAYASHI, H., NISHIYAMA, T., TSUJI, S., IMAI, K., ABO, T., FUJIWARA, M. and SATO, S., Expression of intercellular adhesion molecule-1 on transitional cell cancer. Possible significance in immunity against tumor cells. Amer. J. Pathol., 143, 191-198 (1993).
32. TSUJIMOTO, Y., FINGER, L.R., YUNIS, J., NOWELL, P.C. and CROCE, C.M., Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (Wash.), 226, 1097-1099 (1984).
33. VAN DEN OORD, J.J., VANDEGHINSTE, N., DE LEY, M. and DE WOLF PEETERS, C., Bcl-2 expression in human melanocytes and melanocytic tumors. Amer. J. Pathol., 145, 294-300 (1994).
34. WANG, Y., RAMOVIST, T., SZEKELY, L., AXELSON, H., KLEIN, G. and WIMAN, K.G., Reconstitution of wild type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Diff., 4, 467-473 (1993a).
35. WANG, Y., SZEKELY, L., OKAN, I., KLEIN, G. and WIMAN, K.G., Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene, 8, 3427-3431 (1993b).
36. XIAO-MING, Y., OLTVAI, Z.N. and KORSMEYER, S.J., BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.), 369, 321-323 (1994).
37. YAGODA, A., Chemotherapy of renal cell carcinoma: 1983-1989. Semin. Urol., 7, 199-202 (1989).
38. YANG, E., JOCKEL, J., ZHA, J. and KORSMEYER, S.J., Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 80, 285-291 (1995).
39. YONISH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, L., KIMCHI, A. and OREN, M., Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352, 345-347 (1991).